Diffusion -and Perfusion Weighted MRI for Response Prediction of Symptomatic Leiomyomas Following Uterine Artery Embolization
This trial is active, not recruiting.
|Treatment||diffusion -and perfusion weighted mri including iv contrast agent injection|
|Sponsor||Universitaire Ziekenhuizen Leuven|
|Start date||January 2012|
|End date||December 2015|
|Trial size||100 participants|
|Trial identifier||NCT01514617, S53666|
It is known that volumetric response of leiomyomas following uterine artery embolization correlates well with patients clinical outcome. The aim of this study is to assess diffusion -and perfusion weighted MRI for the prediction of volumetric response following uterine artery embolization in patients with symptomatic leiomyomas.
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
|Masking||single blind (investigator)|
Diffusion -and perfusion weighted MRI as a predictor for volumetric response of leiomyomas after uterine artery embolization
time frame: Participants will be followed for the duration of hospital stay (an expected average of 3 days) and will be systematically followed during their follow-up.
Female participants of any age.
- women with symptomatic leiomyomas
- women with known contra-indications for MRI (cardiac pacemaker, cochlear implants, claustrophobic patients)
- women with contra-indications to gadolinium-based contrast agents (including patients with a known restricted renal function; GFR < 30 mL/min)
|Official title||Diffusion -and Perfusion Weighted MRI for Response Prediction of Symptomatic Leiomyomas Following Uterine Artery Embolization|
|Principal investigator||Geert Maleux, MD, Prof.|
Call for more information